

Acquired Hemophilia A Revealing a Pemphigus: A Case Report

Abstract

Background: Acquired hemophilia A (AHA) is a rare bleeding disorder that affects one to two cases per million people annually and results from the development of autoantibodies directed against coagulation factor VIII.

Case presentation: We report the case of a 63-year-old woman admitted for surgical management of a knee fracture associated with a large hematoma. Laboratory investigations revealed an isolated prolongation of activated partial thromboplastin time (aPTT) not corrected by normal plasma, with a factor VIII activity of 1% and an inhibitor titer of 12.8 BU/mL. One month later, the patient developed cutaneous and mucosal hemorrhagic bullous lesions, and skin biopsy confirmed the diagnosis of pemphigus. She received recombinant factor VIII and high-dose corticosteroids, followed by cyclophosphamide and rituximab.

Conclusion: This case highlights an exceptional association between acquired hemophilia A and pemphigus, emphasizing the importance of early diagnosis and coordinated multidisciplinary management to prevent severe hemorrhagic complications.

Introduction

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by the development of neutralizing antibodies against coagulation factor VIII (1). Its incidence is estimated at 1–2 cases per million people per year. Unlike congenital hemophilia, which is hereditary, AHA occurs later in life and affects both men and women equally.

The clinical presentation varies from mild spontaneous bruising to life-threatening bleeding, often involving muscles or internal organs. Because of its rarity, diagnosis is frequently delayed or mistaken for other conditions (2). The patient care pathway remains complex, often requiring hospitalization, although outpatient management strategies are emerging.

The objective of this work is to describe a case of acquired hemophilia A revealing pemphigus in a 63-year-old woman, and to review the relevant literature.

Keywords: Acquired hemophilia A, anti-FVIII antibodies, autoimmune disease, knee hematoma, pemphigus

Case Report

A 63-year-old woman, with no notable medical history, was admitted for surgical management of a right knee fracture accompanied by an extensive hematoma. She reported the recent onset of cutaneomucosal papules and spontaneous ecchymotic lesions prior to the trauma.

Laboratory investigations:

Preoperative blood work showed hemoglobin 10.3 g/dL, leukocytes $9.8 \times 10^9/L$, and platelets $256 \times 10^9/L$. Prothrombin time (PT) was 82%, while activated partial thromboplastin time (aPTT) was prolonged (ratio = 2.9). The mixing test (Rosner index = 75%) confirmed the presence of an inhibitor. Lupus anticoagulant testing was negative. Coagulation factor assays revealed factor VIII = 1%, factor IX = 113%, factor XI = 74%, and factor XII = 71%. Anti-FVIII antibodies were detected by the Nijmegen method (inhibition = 98%, titer = 12.8 BU/mL), confirming the diagnosis of AHA.

Management:

The patient received recombinant factor VIII and high-dose corticosteroids to control the bleeding and immune response.

Further investigations:

Autoimmune screening was initially negative. One month later, she developed hemorrhagic bullous lesions on the skin and mucosa. Skin biopsy and direct immunofluorescence showed intraepidermal cleavage with intercellular IgG deposition, confirming pemphigus vulgaris.

Outcome:

She was treated with a combination of cyclophosphamide and rituximab, resulting in complete resolution of the hematoma, normalization of the coagulation profile, and improvement of the skin lesions. A relapse occurred during corticosteroid tapering, requiring adjustment of immunosuppressive therapy. The patient was discharged on oral corticosteroids with close follow-up.

Discussion

Hemophilia refers to a bleeding disorder caused by an isolated deficiency of a coagulation factor—factor VIII in hemophilia A and factor IX in hemophilia B. These plasma glycoproteins are essential for thrombin generation and fibrin clot formation. Their deficiency leads to delayed and reduced clot formation, resulting in hemorrhagic manifestations.

Acquired hemophilia develops later in life and affects both sexes equally. It is caused by neutralizing autoantibodies directed against coagulation factors, particularly FVIII or FIX. Most patients present with spontaneous or post-traumatic bleeding of varying severity (1).

Because of its rarity, AHA is often underdiagnosed. Patient management is complex due to diverse hemorrhagic presentations and frequent comorbidities (2). AHA is the most common acquired coagulation disorder, with an incidence of about 1.5 per million per year (3). Although rare, acquired FVIII deficiency is more frequent than acquired FIX deficiency (4,5). Two incidence peaks are described: one between 20 and 30 years (often postpartum) and another after 60 years. Rare pediatric cases have been reported, sometimes linked to transplacental transfer of maternal antibodies (6–8).

Approximately 50% of AHA cases are idiopathic, while the rest are associated with autoimmune diseases, malignancies, pregnancy, or drug exposure (7,9,1). Among autoimmune causes, pemphigus is exceptional. It is characterized by autoantibodies targeting epithelial adhesion proteins (desmosomes), leading to blistering of the skin and mucosa.

The coexistence of pemphigus and AHA likely reflects shared autoimmune mechanisms involving loss of immune tolerance and concurrent antibody production against FVIII and epithelial adhesion proteins (1,7).

Treatment requires an individualized and multidisciplinary approach combining hemostatic therapy (rFVIIa, FEIBA®, or FVIII concentrates) and immunosuppression (corticosteroids, cyclophosphamide, or rituximab) to eradicate inhibitors and control autoimmunity.

Conclusion

The association between acquired hemophilia A and pemphigus highlights the interplay between autoimmune disorders and coagulation defects. Early recognition and multidisciplinary management are essential to prevent life-threatening hemorrhagic complications. Further studies are needed to elucidate the immunopathological links between these rare entities and to optimize therapeutic strategies.

Conflict of Interest

The authors declare no conflict of interest.

Author Contributions

All authors contributed to patient management, manuscript preparation, and literature review. All have approved the final version of this article.

References

1. Zanon E. *Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment*. *Diagnostics (Basel)*. 2023;13(3):420.
2. Guillet B, Aouba A, Borg J-Y, Schved JF, Lévesque H. *Characterizing hospital pathways for the care of acquired hemophilia in France using national health data*. *Rev Med Interne*. 2022;43(3):139–144.
3. Aouba A, Rey G, Pavillon G, Jouglu E, Rothschild C, Torchet M-F, et al. *Deaths associated with acquired haemophilia in France (2000–2009): multiple cause analysis*. *Haemophilia*. 2012;18(3):339–344.
4. Jedidi I, Hdiji S, Ajmi N, Makni F, Masmoudi S, Elloumi M, et al. *Acquired haemophilia B: a case report and literature review*. *Ann Biol Clin (Paris)*. 2011;69(6):685–688.
5. Grossin D, Broner J, Arnaud E, Goulabchand R, Gris JC. *Autoimmune acquired hemophilia: the role of rituximab in therapeutic strategy*. *Rev Med Interne*. 2019;40(9):574–580.
6. Mingot-Castellano ME, Rodríguez-Martorell FJ, Nuñez-Vázquez RJ, Marco P. *Acquired Haemophilia A: A Review of What We Know*. *J Blood Med*. 2022;13:691–710.
7. Windyga J, Baran B, Odnoczek E, Buczman A, Drews K, Laudanski P, et al. *Treatment guidelines for acquired hemophilia A*. *Ginekol Pol*. 2019;90(6):353–364.
8. Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, et al. *Acquired hemophilia A: Updated review of evidence and treatment guidance*. *Am J Hematol*. 2017;92(7):695–705.
9. Franchini M, Gandini G, Di Paolantonio T, Mariani G. *Acquired hemophilia A: A concise review*. *Am J Hematol*. 2005;80(1):55–63.